Abstract: Lamivudine monotherapy is a common choice when holding regimens are used, on the premise that the lamivudine-associated M184V resistance mutation reduces viral replication and may maintain clinical and immunological stability compared with discontinuing treatment altogether.
SURVEILLANCE OF HIV-1 DRUG-RESISTANCE MUTATIONS IN THAILAND FROM 1999 TO 2014.
PMID: 29641878
2017
The Southeast Asian journal of tropical medicine and public health
Abstract: M184I/V was the most common (53.1%prevalence) RT inhibitor (NRTI) mutation.
Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals.
Result: M184V (71%) and M41L (30%) were the two most common NRTI RAMs, and L90M (24%) and V82A (17%) the two most common PI-major RAMs.
Result: The two most common NNRTI RAMs were V179D (16%) and V106I (15%); the most common NRTI RAMs were D67N (29%) and M184V (26%); and the most common PI-major RAMs were M46I (11%) and I84V (9%).
Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.
PMID: 26175454
2016
The Journal of infectious diseases
Abstract: BACKGROUND: Virologic failure in subtype C is characterized by high resistance to first-line antiretroviral (ARV) drugs, including efavirenz, nevirapine, and lamivudine, with nucleoside resistance including type 2 thymidine analog mutations, K65R, a T69del, and M184V.
Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
Discussion: Existing data raise concern that the E138K and M184I mutations can interact to increase viral replication capacity, offsetting the decreased viral fitness usually associated with the M184I/V mutations.
Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Abstract: The most common NRTI mutations were M184V (80%), L74V (31%), L74I (17%), K219E (9%), and M184I (9%), NNRTI mutations were K103N (83%), P225H (14%), L100I (11%), and Y188L (11%), reflecting generally the similar pattern of DRMs to that seen in treatment failed subtype B viruses.
Patterns of HIV-1 Drug-Resistance Mutations among Patients Failing First-Line Antiretroviral Treatment in South India.
PMID: 26385878
2016
Journal of the International Association of Providers of AIDS Care
Abstract: RESULTS: Of the study patients followed up for 6 months, 23 patients failed first-line therapy and the mutation of I135R/T/V/X, L178 I/M, M184V/I, D67N, K70R, and K103N was most common.
Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.
Abstract: Baseline minority nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) RAMs M184V and L210W were each detected in one VF (none in responders).
HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey.
PMID: 26414663
2016
AIDS research and human retroviruses
Abstract: Primary drug resistance mutations (K65R, M184V) and thymidine analogue-associated mutations (TAMs) were evaluated together as nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations.
Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study.
Abstract: Sixteen (6%) patients experienced virological failure, which was associated with the presence of the M184V/I resistance mutation in prior genotypes (P=0.02) and the use of a non-NNRTI as third agent before the switch (P=0.03).
HIV mutation literature information.
PMID: 
2017
South African medical journal
Browser Board
Co-occurred Entities
Filtrator
ViMRT